S-Space

Browse

Author

Showing results 1 to 3 of 3

Issue Date	Title / Author(s) / Citation	File
2019-02	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer Bang, Y. -J.; Kang, Y. -K.; Ng, M.; Chung, H. C.; Wainberg, Z. A.; Gendreau, S.; Chan, W. Y.; Xu, N.; Maslyar, D.; Meng, R.; Chau, I; Ajani, J. A. European Journal of Cancer, Vol.108, pp.17-24	DOI
2021-09	Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma Shitara, K.; Ozguroglu, M.; Bang, Y-J; Di Bartolomeo, M.; Mandala, M.; Ryu, M-H; Caglevic, C.; Chung, H. C.; Muro, K.; Van Cutsem, E.; Kobie, J.; Cristescu, R.; Aurora-Garg, D.; Lu, J.; Shih, C-S; Adelberg, D.; Cao, Z. A.; Fuchs, C. S. Annals of Oncology, Vol.32 No.9, pp.1127-1136	DOI
2022-02	First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer Niu, J.; Maurice-Dror, C.; Lee, D. H.; Kim, D. -W.; Nagrial, A.; Voskoboynik, M.; Chung, H. C.; Mileham, K.; Vaishampayan, U.; Rasco, D.; Golan, T.; Bauer, T. M.; Jimeno, A.; Chung, V.; Chartash, E.; Lala, M.; Chen, Q.; Healy, J. A.; Ahn, M. -J. Annals of Oncology, Vol.33 No.2, pp.169-180	DOI